[go: up one dir, main page]

MX357009B - Vacunas contra el virus de la influenza y sus usos. - Google Patents

Vacunas contra el virus de la influenza y sus usos.

Info

Publication number
MX357009B
MX357009B MX2014006396A MX2014006396A MX357009B MX 357009 B MX357009 B MX 357009B MX 2014006396 A MX2014006396 A MX 2014006396A MX 2014006396 A MX2014006396 A MX 2014006396A MX 357009 B MX357009 B MX 357009B
Authority
MX
Mexico
Prior art keywords
domain
polypeptides
influenza hemagglutinin
influenza virus
virus vaccines
Prior art date
Application number
MX2014006396A
Other languages
English (en)
Other versions
MX2014006396A (es
Inventor
Wilem Meijberg Jan
Impagliazzo Antonietta
Vogels Ronald
Heinz Edward Friesen Robert
Alard Philippe
Loverix Stefan
Radosevic Katarina
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of MX2014006396A publication Critical patent/MX2014006396A/es
Publication of MX357009B publication Critical patent/MX357009B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C07K16/108—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a Polipéptidos que comprenden polipéptidos del dominio de tallo de la hemaglutinina de la influenza, donde dichos polipéptidos comprenden (a) un dominio HA1 de la hemaglutinina de la influenza, que comprende un segmento del tallo N-terminal del HA1, unido covalentemente mediante una secuencia conectora de 0-50 aminoácidos a un segmento del tallo C-terminal del HA1, y (b) un dominio HA2 de la hemaglutinina de la influenza en el que se han mutado uno o más aminoácidos. También se proveen ácidos nucleicos que codifican dichos polipéptidos, composiciones que comprenden a los polipéptidos y/o a las moléculas de ácidos nucleicos; así como métodos para usarlos, en particular en la detección, la prevención y/o el tratamiento de la influenza.
MX2014006396A 2011-11-28 2012-11-27 Vacunas contra el virus de la influenza y sus usos. MX357009B (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564086P 2011-11-28 2011-11-28
US201161564198P 2011-11-28 2011-11-28
EP11191003 2011-11-28
EP11191009 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
MX2014006396A MX2014006396A (es) 2014-07-22
MX357009B true MX357009B (es) 2018-06-22

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006396A MX357009B (es) 2011-11-28 2012-11-27 Vacunas contra el virus de la influenza y sus usos.

Country Status (20)

Country Link
US (3) US9452211B2 (es)
EP (2) EP2785372B1 (es)
JP (1) JP6294828B2 (es)
KR (1) KR101983989B1 (es)
CN (1) CN104066446B (es)
AR (1) AR089005A1 (es)
AU (1) AU2012343981B2 (es)
BR (1) BR112014012681A8 (es)
CA (1) CA2857087C (es)
EA (1) EA033386B1 (es)
HK (1) HK1199211A1 (es)
IL (1) IL232780A (es)
IN (1) IN2014CN04742A (es)
MX (1) MX357009B (es)
MY (1) MY170927A (es)
PH (1) PH12014501118B1 (es)
SG (1) SG11201402633UA (es)
TW (1) TWI618715B (es)
WO (1) WO2013079473A1 (es)
ZA (1) ZA201404797B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010234849B2 (en) 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
KR20130075732A (ko) 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
CN104582714A (zh) * 2012-05-23 2015-04-29 斯坦福大学托管董事会 流感疫苗构建体
ES2929942T3 (es) 2012-12-18 2022-12-05 Icahn School Med Mount Sinai Vacunas contra el virus de la gripe y sus usos
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
MY190097A (en) * 2013-05-30 2022-03-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP6704849B2 (ja) * 2013-08-03 2020-06-03 アバター・メディカル・エルエルシー インフルエンザヘマグルチニンタンパク質およびその方法
EP3137487B1 (en) 2014-05-01 2021-03-03 Indian Institute of Science Polypeptides for generating anti-influenza antibodies and uses thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP6641305B2 (ja) 2014-06-26 2020-02-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
BR112016030577A8 (pt) * 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes
JP6735269B2 (ja) * 2014-07-10 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
WO2016180826A1 (en) * 2015-05-11 2016-11-17 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
AU2016316723B2 (en) * 2015-09-02 2021-03-25 Janssen Vaccines & Prevention B.V. Stabilized viral class I fusion proteins
US11266734B2 (en) 2016-06-15 2022-03-08 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN110167585B (zh) 2016-09-02 2024-03-08 美国卫生与公众服务部 稳定化的第2组流感血凝素茎区三聚体及其用途
WO2018053178A1 (en) * 2016-09-16 2018-03-22 Vaccitech, Inc. Compositions and methods for vaccination against influenza
EP3528827A4 (en) * 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. Influenza hemagglutinin protein vaccines
EP3606555A4 (en) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
US11413345B2 (en) 2017-11-22 2022-08-16 Her Majestry the Queen in Right of Canada as Represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
EP4119154A1 (en) * 2018-01-23 2023-01-18 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
JP2021528972A (ja) 2018-06-27 2021-10-28 メディカゴ インコーポレイテッド インフルエンザウイルスヘマグルチニン変異体
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CA3137448A1 (en) * 2019-04-25 2020-10-29 Janssen Vaccines & Prevention B.V. Recombinant influenza antigens
WO2021043869A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
AU2020367242B2 (en) * 2019-10-15 2026-02-12 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
KR20230038416A (ko) * 2020-05-08 2023-03-20 아카데미아 시니카 키메릭 인플루엔자 백신
WO2022051327A1 (en) * 2020-09-02 2022-03-10 St. Jude Children's Research Hospital, Inc. Hemagglutinin modifications for improved influenza vaccine production
WO2022049276A1 (en) 2020-09-07 2022-03-10 Intervet International B.V. Ha stem vaccine for ha antibody-positive targets
JP2024528504A (ja) * 2021-06-28 2024-07-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規インフルエンザ抗原
KR20250069712A (ko) * 2022-08-16 2025-05-19 세퀴러스 인코포레이티드 변형 인플루엔자 바이러스
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116874607B (zh) * 2023-06-09 2024-12-10 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用
WO2025038983A1 (en) * 2023-08-17 2025-02-20 Colorado State University Research Foundation Inactivated whole virion vaccine against influenza and methods of use thereof
WO2025149907A1 (en) * 2024-01-08 2025-07-17 Seqirus Inc. Influenza vaccines

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
ATE315095T1 (de) 2000-08-10 2006-02-15 Crucell Holland Bv Adenovirenvektoren zur transduktion der chondrozyten
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
CN100497639C (zh) 2002-04-25 2009-06-10 克鲁塞尔荷兰公司 生产腺病毒载体的手段和方法
EP1497440B1 (en) 2002-04-25 2008-08-20 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2004278517B2 (en) 2003-10-02 2010-04-01 Crucell Holland B.V. Packaging cells for recombinant adenovirus
CN101090974B (zh) 2004-11-16 2011-05-11 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
AU2010234849B2 (en) * 2009-03-30 2017-06-22 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
KR20130075732A (ko) * 2010-03-30 2013-07-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
AU2011310838B2 (en) 2010-09-27 2015-11-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
ES2608321T3 (es) 2011-07-14 2017-04-07 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas capaces de neutralizar virus de la gripe A del grupo filogenético 1 y del grupo filogenético 2 y virus de la gripe B
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
MX357009B (es) 2011-11-28 2018-06-22 Crucell Holland Bv Vacunas contra el virus de la influenza y sus usos.
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
MY170407A (en) 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
US9512201B2 (en) 2012-09-27 2016-12-06 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing hepatitis B viruses and uses thereof
MY190097A (en) 2013-05-30 2022-03-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP6735269B2 (ja) 2014-07-10 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． インフルエンザウイルスワクチンおよびその使用
BR112016030577A8 (pt) 2014-07-10 2021-07-20 Janssen Vaccines & Prevention Bv polipeptídeos multiméricos do domínio de haste da hemaglutinina da gripe, molécula de ácido nucleico, vetor, composição e usos destes

Also Published As

Publication number Publication date
IL232780A (en) 2017-09-28
IL232780A0 (en) 2014-07-31
KR101983989B1 (ko) 2019-05-31
JP2015502353A (ja) 2015-01-22
CN104066446A (zh) 2014-09-24
EA033386B1 (ru) 2019-10-31
ZA201404797B (en) 2022-03-30
EA201491051A1 (ru) 2015-04-30
MY170927A (en) 2019-09-19
EP3566714A1 (en) 2019-11-13
US9452211B2 (en) 2016-09-27
CA2857087A1 (en) 2013-06-06
NZ625973A (en) 2016-09-30
US20160362455A1 (en) 2016-12-15
US9969778B2 (en) 2018-05-15
SG11201402633UA (en) 2014-09-26
US20140357845A1 (en) 2014-12-04
KR20140099515A (ko) 2014-08-12
HK1199211A1 (en) 2015-06-26
MX2014006396A (es) 2014-07-22
BR112014012681A2 (pt) 2017-06-13
BR112014012681A8 (pt) 2017-06-20
PH12014501118A1 (en) 2014-08-04
AR089005A1 (es) 2014-07-23
CA2857087C (en) 2021-05-25
WO2013079473A1 (en) 2013-06-06
AU2012343981B2 (en) 2017-09-07
IN2014CN04742A (es) 2015-09-18
JP6294828B2 (ja) 2018-03-14
EP2785372A1 (en) 2014-10-08
PH12014501118B1 (en) 2019-03-01
EP2785372B1 (en) 2019-06-19
TW201329101A (zh) 2013-07-16
US20160355553A1 (en) 2016-12-08
CN104066446B (zh) 2017-10-03
TWI618715B (zh) 2018-03-21
AU2012343981A1 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
PH12014501118A1 (en) Influenza virus vaccines and uses thereof
PH12015502612A1 (en) Influenza virus vaccines and uses thereof
WO2013152351A3 (en) Fusion polypeptides and methods of use thereof
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
PH12013502479A1 (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
CY1119916T1 (el) Ανοσογονικη συνθεση
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
IN2014DN05805A (es)
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
MX2021000030A (es) Metodos y composiciones que utilizan polipeptidos variantes klotho.
IN2014DN07399A (es)
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
IN2014DN05695A (es)
MX371403B (es) Moleculas de andamiaje a base de fibronectina estabilizada.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
PH12013500204A1 (en) Polypeptides for treating and/or limiting influenza infection
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
IN2015DN03070A (es)
EP3925968A3 (en) Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
WO2011138032A3 (en) Universal influenza vaccines and methods for their generation
SG10201908920QA (en) Influenza virus vaccines and uses thereof

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SANDVIK HYPERION AB

FG Grant or registration